End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.62 CNY | +1.53% | +0.09% | -12.39% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.39% | 1.25B | - | ||
+39.82% | 731B | C+ | ||
+31.34% | 586B | B | ||
-7.31% | 348B | C+ | ||
+14.23% | 319B | B- | ||
+0.86% | 273B | C+ | ||
+13.47% | 235B | B+ | ||
-6.63% | 203B | A+ | ||
+7.49% | 202B | B- | ||
+4.51% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 605116 Stock
- Ratings Aurisco Pharmaceutical Co.,Ltd.